Moderate to Severe Ulcerative Colitis Clinical Trial
Official title:
Fecal Calprotectin Levels, QoL and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
The objectives of this study are to explore the effect of adalimumab on the fecal Calprotectin level of Ulcerative Colitis (UC) patients and the correlation with their general well-being (QoL), work ability and disease activity.
This is a non-interventional, observational study in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication. The assignment of the patient to a Humira containing regimen has to be decided in advance and has to be current practice. The prescription of Humira is clearly separated from the decision to include the participant in this study. ;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03627052 -
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT05486104 -
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT04879966 -
A Cohort Study Comparing IFX to CS for Moderate to Severe UC
|
||
Completed |
NCT04700449 -
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
|
Phase 2 | |
Completed |
NCT04090411 -
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
|
Phase 2 |